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Abstract
Background: RGS9-deficient mice show drug-induced dyskinesia but normal locomotor activity under unchallenged
conditions.
Results: Genes related to Ca2+ signaling and their functions were regulated in RGS9-deficient mice.
Conclusion: Changes in Ca2+ signaling that compensate for RGS9 loss-of-function can explain the normal locomotor activity
in RGS9-deficient mice under unchallenged conditions.
Significance: Identified signaling components may represent novel targets in antidyskinetic therapy. The long splice variant
of the regulator of G-protein signaling 9 (RGS9-2) is enriched in striatal medium spiny neurons and dampens dopamine D2
receptor signaling. Lack of RGS9-2 can promote while its overexpression prevents drug-induced dyskinesia. Other animal
models of drug-induced dyskinesia rather pointed towards overactivity of dopamine receptor-mediated signaling. To
evaluate changes in signaling pathways mRNA expression levels were determined and compared in wild-type and RGS9-
deficient mice. Unexpectedly, expression levels of dopamine receptors were unchanged in RGS9-deficient mice, while
several genes related to Ca2+ signaling and long-term depression were differentially expressed when compared to wild type
animals. Detailed investigations at the protein level revealed hyperphosphorylation of DARPP32 at Thr34 and of ERK1/2 in
striata of RGS9-deficient mice. Whole cell patch clamp recordings showed that spontaneous synaptic events are increased
(frequency and size) in RGS9-deficient mice while long-term depression is reduced in acute brain slices. These changes are
compatible with a Ca2+-induced potentiation of dopamine receptor signaling which may contribute to the drug-induced
dyskinesia in RGS9-deficient mice.
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Introduction
Drug-induced dyskinesia is an important clinical challenge in
both Parkinsonian patients treated with L-DOPA and/or dopa-
mine agonists and patients receiving neuroleptics. Since both
classes of drugs primarily act via dopamine receptors, it is
generally accepted that modulation of downstream signaling of
these molecules forms the primary event in the pathophysiology of
such movement disorders [1]. However, animal models for drug-
induced dyskinesia to dissect involved signaling pathways down-
stream of the dopamine receptors are sparse. Cenci and colleagues
characterized L-DOPA-induced dyskinesia (LID) in rats that were
first rendered hemiparkinsonian via unilateral midbrain injections
of 6-hydroxydopamine and subsequently treated with rather high
doses of L-DOPA [2]. Dopamine receptors are pharmacologically
differentiated into the dopamine D1 (D1R) and the dopamine D2
receptor (D2R) families [3]. While the former activates adenylyl
cyclases (AC) via Gas and Gaolf the latter inhibits AC acting via
Gai (AC types I, V, VI) and Gao (AC type I) [4–5]. D2R agonists
can provoke dyskinesia in clinical stages of dopamine deficiency
[1,6–7] and inhibition of D1R signaling prevented dyskinesia in
hemiparkinsonian rats [8]. Further evidence that excessive
dopamine receptor signaling is involved in dyskinesia was provided
by rodent and primate studies overexpressing GRK6 [9]. GRK6 is
a G protein-coupled receptor kinase which controls desensitization
of dopamine receptors.
RGS9-deficient mice represent a genetic animal model for the
phenotype of drug-induced dyskinesia [10–12]. Lack of this
accessory protein of GPCR signaling seems to predispose for L-
DOPA and neuroleptic-induced dyskinesias [10]. Regulators of G-
protein signaling (RGS) form a heterogeneous family of GTPase
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activating proteins (GAP) that in addition to accelerating G-
protein turnover have multiple other functions [13]. RGS proteins
regulate a variety of Ga subunits, but do not interact with
stimulatory Gas proteins. However, Gb5 is an obligate binding
partner to RGS9-2 and this dimeric complex has been recently
shown to directly modulate adenylyl cyclase function [14]. The
striatum is the major target of dopaminergic pathways in the CNS
and contains most of the postsynaptic dopamine receptors. It also
bears the highest expression levels of the long splice variant of the
ninth member of the RGS family (RGS9-2) [15–16]. Modulation
of striatal dopaminergic transmission by RGS9-2 is most likely
restricted to D2R signaling as D1R are mainly coupled to Gaolf in
striatum but also Gas in other tissues [16–17].
Mice lacking RGS9 display increased abnormal involuntary
movements following dopamine depletion and subsequent admin-
istration of dopamine receptor agonists or L-DOPA [10].
Consistently, overexpression of RGS9 in dyskinetic non-human
primates resulted in a reduction of such L-DOPA-induced
dyskinesia [12]. The functional interaction of D2R and RGS9-2
is supported by the increased fraction of high affinity D2R present
in RGS9-deficient mice [18]. Accordingly, in a rat model of
schizophrenia with sensitization to amphetamine and in patients
suffering from schizophrenia, reduced levels of RGS9 were
detected [11]. It is therefore very likely that RGS9-2 has important
functional effects on D2R-mediated signaling of striatal medium
spiny neurons (sMSN) most likely mediated by accelerating the
GTPase activity of G proteins.
Although an enhanced striatal D2R-dependent dopaminergic
signal transduction and some deficits in working memory and
motor coordination [16], RGS9-deficient mice show an almost
normal motor phenotype under unchallenged conditions [19].
However, in RGS9-deficient mice that are treated with the D2R-
specific agonist quinpirole following pretreatment with reserpine
exhibit pronounced dyskinesia that is absent in wild-type (wt) mice
[10]. Under the circumstance of reserpine-dependent depletion of
dopaminergic transmission, striatal dysfunction becomes un-
masked that is normally balanced by compensatory changes on
the functional or gene regulation level. A similar situation may be
present, when drug-induced dyskinesia develops either in patients
with Parkinson’s disease or schizophrenia receiving long-term
therapy with L-DOPA or neuroleptics. The analysis of compen-
satory gene regulation in functional dopaminergic dysbalance may
thus help both understanding the pathophysiology of drug-induced
dyskinesia and identifying novel targets for antidyskinetic therapy.
Therefore, we screened for compensatory changes in striata of
RGS9-deficient mice. Based on the function of RGS9 in D2R
signaling we hypothesized that RGS9-deficient mice should
display decreased cAMP signaling as a consequence of overactive
D2R. We found no evidence for decreased cAMP signaling but
rather detected molecular changes in Ca2+ signaling. Our data
point towards a Ca2+-induced potentiation of dopamine receptor
signaling that may contribute to drug-induced dyskinesia in
RGS9-deficient mice.
Materials and Methods
RGS9-deficient Mouse Strain and Mouse Genotyping
The generation and initial characterization of the RGS9-
deficient mice was reported previously [20]. All animal experi-
ments were conducted with mice on a C57Bl6 background (.12
generations) and in accord with accepted standards of animal care
(NIH guidelines) and approved by the respective regional
government agency of Saxony (Regierungspra¨sidium Leipzig,
TV 42/08).
Genotyping was done by PCR using mouse tail DNA and three
primers. The two reverse primers complementary annealed either
to MC1neopA-cassette in the inactivated RGS9 gene (59-
GGCTATGACTGGGCACAACA -39) or to the sequence that
is substituted by MC1neopA-cassette in RGS9-deficient mice (59-
ACAGCGGAAGCCATAGAGGA -39). The attribution of the
genotype resulted from the different size of the PCR product with
the forward-primer (59- TTGGGCTCTTGCTCGTGTTA -39)
(94uC for 2 min; 35 cycles of 94uC for 30 sec, 61uC for 30 sec,
72uC for 90 sec; 72uC for 10 min).
RNA Isolation and Microarray Expression Analysis
Striata (dorsal and ventral part) of 3-month-old wt and RGS9-
deficient male mice were isolated by microdissection and total
RNA was isolated using TRIzol reagent (Life Technologies,
Carlsbad, USA) according to the manufacturer’s instructions. The
RNA was further purified using the SV Total RNA Isolation
System (Promega, Mannheim, Germany) according to the
manual. For microarray analysis, RNA integrity and concentra-
tion were quantified on an Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, USA) using the RNA 6.000 LabChip Kit
(Agilent Technologies, Palo Alto, USA).
For reverse transcription (SuperScript II, Life Technologies,
Carlsbad, USA) of total striatal RNA (1 mg) from 5 wt and 5
RGS9-deficient mice, an oligo-dT primer containing a T7 RNA
polymerase promoter site (Genset SA, Paris, France) was used.
After purification of cDNA by phenol-chloroform extraction,
in vitro transcription using ENZO BioArray RNA transcript
labeling kit (Affymetrix, Santa Clara, USA) was performed.
Unincorporated nucleotides were removed using the RNeasy kit.
Fragmented cRNA was hybridized to GeneChip Mouse Genome
Arrays 430 2.0 (Affymetrix, Santa Clara, USA) at the IZKF
Leipzig microarray core facility.
The expression data were normalized with the Microarray Suite
5 (MAS5) algorithm using the R software package (http://www.r-
project.org/). The annotation of the probe sets was obtained from
the Affymetrix homepage. The datasets were filtered for
transcripts that were detected as present in at least three
microarrays of one group (wt or RGS9-deficient mice) [21].
Statistical testing was done using a two-tailed Student’s t-test. For
gene ontology profiling, MAS5 normalized data with P#0.01 were
subjected to the Onto Express algorithm [22–23]. The settings
were: hypergeometric distribution, correction for false discovery
rate (fdr). The MAS5 processed data were also analyzed using the
Gene Set Enrichment Analysis (GSEA) algorithm [24]. Gene sets
were obtained from the Kyoto Encyclopedia of Genes and
Genomes database (KEGG) [25]. GSEA settings were: 500
phenotype permutations, datasets collapsed to gene symbols and
weighted enrichment with signal-to-noise metric.
Preparation of cDNA and Quantification by Real-time PCR
For quantitative real-time PCR analysis (qPCR), Platinum
SYBR Green qPCR Supermix (Life Technologies, Carlsbad,
USA), cDNA from 30 ng total RNA, 0.6 mM forward and reverse
primers and 100 nM ROX (5-carboxy-X-rhodamine, passive
references dye) were used. Oligonucleotide primers (Table S1 in
File S1) were designed using the Primer3 software [26] to flank
intron sequences if possible. PCR was performed in an MX 3000P
instrument (Stratagene, La Jolla, USA) using the following
protocol: 2 min 50uC, 2 min 95uC and 50 cycles of 15 s 95uC,
30 s 60uC. To confirm the presence of a single amplicon, product
melting curves were recorded. The correct size of the amplicons
was asserted by agarose gel electrophoresis and the identity
verified by restriction enzyme cleavage or sequencing for at least
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10% of the amplicons. Threshold cycle (CT) values were set within
the exponential phase of the PCR. Data were normalized to b2-
microglobulin and DCT values were used to calculate the relative
expression levels [27]. Gene regulation was statistically evaluated
by subjecting the DDCT values (DCT RGS9-deficient minus DCT
wt) to a two-tailed Student’s t-test assuming equal variances. Gene
regulation values are given as 22DDCT 6 SEM.
Western Blot Analysis
Striata of wt and RGS9-deficient mice were homogenized by
sonication in phosphate buffered saline (PBS) containing 1 mM
Na2EDTA and a protease inhibitor cocktail (Roche, Basel,
Switzerland). The protein content was determined using Bradford
reagent (Bio-Rad, Hercules, USA). 50 mg or 20 mg total protein
were subjected to 10 or 12.5% SDS-PAGE and transferred onto
nitrocellulose membrane (Hybond-C Extra, Amersham, Piscat-
away, USA). After blocking with 5% non-fat dry milk in Tris-
buffered saline (50 mM Tris, pH 7.6, 150 mM NaCl) containing
0.1% Tween-20 (TBST) for 2 h at 4uC, the blots were incubated
with primary antibody for 1 h at room temperature or over night
at 4uC. The primary antibodies were: anti-RGS9 (Santa Cruz
Biotechnology Inc., Dallas, USA), anti-phosphoDARPP32 (Thr34)
and (Thr75) (Cell Signaling, Boston, USA), anti-DARPP32 (Cell
Signaling, Boston, USA), anti-phospho-p44/42 MAPK (Cell
Signaling, Boston, USA), anti-MAPK (Zymed Laboratories Inc.,
San Francisco, USA), anti-CaMKIIb (ProteinTech Group Inc.,
Chicago, USA), anti-phospho-Thr286 CaMKII (PhosphoSolu-
tions, Aurora, USA), anti-CaMKIIc (Santa Cruz Biotechnology
Inc., Dallas, USA), anti-GluR2 (Santa Cruz Biotechnology Inc.,
Dallas, USA) and anti-actin (Molecular Probes, Eugene, USA).
The dilution of primary antibodies was 1:1000, except for anti-
CaMKIIc (1:500) and anti-GluR2 (1:200). After extensive washing
in TBST, membranes were incubated with horseradish peroxi-
dase-linked anti-mouse, -goat or -rabbit secondary antibody
(Dianova, Hamburg, Germany) diluted 1:10,000 in TBST for
1 h at room temperature. After extensive washing with TBST,
immunostaining was performed using ECL Western Blotting
Substrate (PIERCE, Rockford, USA). Band densitometry was
carried out using the Scion Image software (Scion, Frederick,
USA). Values are given as mean 6 SEM. Protein concentrations
were statistically evaluated using a two-tailed Student’s t-test
assuming equal variances.
Cyclic AMP Measurements in Acute Striatal Samples
Striatal samples of defined size were dissected and individually
transferred into ice-cold stimulation buffer (0.1% BSA, 0.5 mM
IBMX, 5 mM HEPES in HBSS, pH 7.4) containing forskolin at
the given concentrations. To investigate the influence of D2R
signaling on adenylyl cyclase activity, 10 mM forskolin and
quinpirole between 0.01 and 100 mM were added. After stimu-
lation at 37uC for 1 h, samples were transferred into 500 ml ice-
cold 0.1 N HCl, homogenized by sonication for 15 sec at 4uC (1
cycle, 100% amplitude, UP-50 H, Hielscher Ultrasonics) and
incubated on ice for 30 min. Homogenates were centrifuged for
10 min and 140006g at 4uC. Supernatants were transferred into
new reaction tubes and dried at 56uC over night. Pellets were
dissolved in 100 ml lysis buffer (5 mM HEPES, pH 7.4, 0.1%
BSA, 1 mM IBMX, 0.3% Tween-20) and the cAMP concentra-
tion was measured in an AlphaScreen-based assay (Perkin Elmer,
Waltham, USA) according to the manufacturer’s instructions.
Electrophysiological Recordings
Coronal slices (300 mm thick) containing the striatum were
prepared from the brains of RGS9-deficient mice and their wt
littermates. Slices were superfused with an artificial cerebrospinal
fluid (ACSF) containing (in mM): 125 NaCl, 2.5 KCl, 2 CaCl2,
1 MgCl2, 26 NaHCO3, 1.25 NaH2PO4, and 20 glucose, bubbled
with 95% O2/5% CO2. The pH was adjusted to 7.3–7.4 and the
osmolarity to 305 mOsM. We did not suppress GABAA receptor
currents, since we were recording at a holding potential of –70 mV
close to the chloride reversal potential. All recordings were
performed at room temperature. sMSN were identified by their
morphology and characteristic electrophysiological properties
including negative resting membrane potentials and slow capac-
itance transients. To confirm the morphology typical for sMSN,
we labeled some cells (n = 5) using 200 mM Oregon-green-
BAPTA1 (Life Technologies, Carlsbad, USA) and imaged these
cells using a confocal microscope (Olympus Fluoview FV1000).
For analyses, cells were accepted if the leak current was ,100 pA
and the resting membrane potential below –70 mV to ensure
homogenous recordings.
Glass electrodes (5–8 MV) were filled with a solution containing
(in mM): 150 potassium gluconate, 10 NaCl, 3 Mg-ATP, 0.3
GTP, 10 HEPES and 0.05 EGTA, adjusted to pH 7.3 and an
osmolarity of 305 mOsM. The liquid junction potential of 15 mV
was corrected post hoc.
Spontaneous excitatory postsynaptic potentials (sEPSPs) were
recorded at –70 mV. We did not apply tetrodotoxin but applied
CNQX in some of the recorded neurons to confirm that AMPA
receptor activations were the source of spontaneous postsynaptic
activity. Spontaneous postsynaptic potentials were analyzed using
ClampFit 9 software and the event detection, template search
mode (Axon Instruments, Foster City, USA). Templates were
generated by averaging 10 characteristic events.
Excitatory sMSN afferents were stimulated with a glass
electrode filled with ACSF and placed between the recorded
sMSN and the cortex, typically ,50–100 mm from the cell body
using current clamp mode. Stimulus intensity was adjusted to yield
large EPSP amplitudes without eliciting an action potential or
inducing direct stimulation. Typically, we used 100–200 mA for
duration of 0.1 s. Continuous stimulation was performed at a
frequency of 0.5 Hz. Following 20 min of baseline stimulation, we
applied 3 bursts of 3 s duration and a frequency of 100 Hz
separated by 30 s. LTD was then measured for 30 min. Data
points were calculated every 30 s by averaging the last 15 EPSPs
(0.5 Hz). All recordings were performed using a Multiclamp
amplifier (Axon Instruments, Union City, USA), filtered at 2 kHz
and digitized at 10 kHz. Acquisition and analysis were performed
using custom Clampex 9 software (see above). LTD data were
analyzed using a two-tailed Student’s t-test. Data are expressed as
mean 6 SEM.
Results
Transcriptome-wide Striatal Gene Expression Analysis
To identify adaptive gene regulation in response to RGS9
deficiency, striatal gene expression was assayed on a whole
transcriptome-scale in 3-month-old male RGS9-deficient and wt
mice. RNA was prepared from striatal tissue, reversely transcribed
and subjected to Affymetrix microarray hybridization.
To validate the microarray data, we first analyzed relative
expression levels of the RGS9 transcript. Surprisingly, the RGS9
transcript was found significantly up-regulated in the striata of
RGS9-deficient mice (Table S5 in File S1). These data were
confirmed by qPCR (Table 1; Table S4 in File S1). Besides the
catalytic RGS domain, RGS9 contains GGL and DEP domains
[28–29], the latter of which had been substituted in frame by an
MC1neopA-cassette to generate the RGS9-deficient mice. Two
Adaptive Gene Regulation in RGS9-Deficient Mice
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transcript variants of RGS9 were detected in RGS9-deficient
mice, one long including the MC1neopA-cassette and one
truncated variant where the MC1neopA-cassette was missing
[20]. Elevated transcript concentration of RGS9 detected in striata
of RGS9-deficient mice resulted from both transcript variants
since RGS9 probe sets and qPCR primer bound to C-terminal
regions that were available in both transcript variants. Our
Western blot analysis confirmed absence of RGS9 protein in
striatal tissue of RGS9-deficient mice [20] (data not shown). This is
because the resulting mRNAs did not encode for immunoreactive
RGS9 proteins. One can speculate that the up-regulation of the
RGS9 transcript variants may be directed towards balancing the
lack of RGS9 protein. Indeed, a large fraction of differentially
expressed genes belong to the GO category ‘DNA-dependent
regulation of transcription’ (Table S2 in File S1). Because the
promoter of RGS9 and its regulation is not characterized yet, we
did not follow this interesting finding.
Of 45,101 probe sets assayed in the microarray hybridization
experiments, 22,962 probe sets, corresponding to 12,714 genes,
were detected as present ($3 present calls in at least one group)
using the MAS5 algorithm. To determine the extent of differences
in gene expression, we subjected the MAS5-processed microarray
data to statistical analysis. We found that 2.6% (365 probe sets,
corresponding to 327 genes) were significantly different between
wt and RGS9-deficient mice (P#0.01) (the complete list of
differentially expressed transcripts is given on request). We then
used the OntoExpress software [22] to identify functional systems
that show global differences in gene expression between wt and
RGS9-deficient mice (Table S2 in File S1). Differentially expressed
transcripts grouped into processes which included transcription,
synaptic transmission, posttranslational protein modification like
dephosphorylation and palmitoylation, and locomotor behavior
(Table S2 in File S1). In a complementary approach, full array
data were subjected to gene set enrichment analysis (GSEA) [24]
using predefined gene sets obtained from the KEGG database
[25]. Genes that are involved in Ca2+ signaling and in long-term
depression (LTD), a main form of synaptic plasticity, were
differentially expressed between wt and RGS9-deficient mice
(Table S3 in File S1).
Expression Analysis of Genes Involved in Ca2+ Signaling
and Synaptic Plasticity
To verify the differences in gene expression identified by
microarray analysis, we performed qPCR for selected transcripts
involved in D2R signaling, Ca2+ signaling and the two forms of
synaptic plasticity, LTD and long-term potentiation (LTP).
Verification of microarray data is strongly recommended since
different probe set data for one gene can vary in array analyses (see
Table S4 in File S1) and microarray and qPCR data do not always
show strong correlation [30–32]. We therefore considered as
differentially expressed only transcripts that revealed similar
tendency in both methods and were significantly regulated at
least in one of the methods.
Concerning D2R signaling pathway, there was no alteration in
D2R transcript concentration (Table S4 in File S1) but the G-
protein ai subunits 1–3, the adenylyl cyclase 3 (AC3), the catalytic
Table 1. Expression analysis using qPCR of selected transcripts involved in LTD, LTP and Ca2+ signaling.
Trancript gene symbol qPCR signal transduction pathway
adenylate cyclase 3 (AC3) Adcy3 0.7760.06** (9) Ca2+
adenylate cyclase 5 (AC5) Adcy5 0.8760.42 (6) Ca2+
ATPase, Ca2+ transporting, cardiac muscle, slow twitch 2 (SERCA2) Atp2a2 0.5660.1** (6) Ca2+
calmodulin 1 (CaM1) Calm1 0.2760.12* (6) LTP Ca2+
Ca2+/calmodulin-dependent protein kinase II, beta (CaMK II) Camk2b 0.7460.08* (6) LTP Ca2+
Ca2+/calmodulin-dependent protein kinase II gamma (CaMK II) Camk2g 0.6960.04*** (6) LTP Ca2+
Guanine nucleotide binding protein, alpha inhibiting 1 (Gia1) Gnai1 0.5460.11* (6) LTD
Guanine nucleotide binding protein, alpha inhibiting 2 (Gia2) Gnai2 0.5660.11* (6) LTD
Guanine nucleotide binding protein, alpha inhibiting 3 (Gia3) Gnai3 0.4560.12* (6) LTD
Guanine nucleotide binding protein, alpha q polypeptide (Gqa) Gnaq 0.6060.12* (6) LTD LTP Ca2+
glutamate receptor, ionotropic, AMPA2 (alpha 2) (GluR2) Gria2 0.6660.07** (6) LTD LTP
glutamate receptor, metabotropic 5 (mGlu5) Grm5 0.8260.07* (9) LTD LTP Ca2+
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-Ras2) Kras 0.4360.14* (6) LTD LTP
mitogen activated protein kinase 3 (ERK1) Mapk3 0.5460.1** (6) LTD LTP
Phosphodiesterase 4B, cAMP specific (PDE4b) Pde4b 0.6660.12* (6)
phospholipase C, beta 1 (Plcb1) Plcb1 0.5360.11* (6) LTD LTP Ca2+
protein phosphatase 1, regulatory (inhibitor) subunit 1B (DARPP32) Ppp1r1b 0.7660.05** (6)
protein kinase, cAMP dependent, catalytic, beta (PKA) Prkacb 0.6760.11* (9) LTP Ca2+
Protein kinase C, beta 1 (PKC) Prkcb1 0.5160.09** (6) LTD LTP Ca2+
Rap guanine nucleotide exchange factor (GEF) 3 Rapgef3 0.6660.1* (9) LTP
Regulator of G-protein signaling 9 (RGS9) Rgs9 1.4760.2* (6)
Ryanodine receptor 1, skeletal muscle Ryr1 0.1960.04*** (6) LTD Ca2+
Gene expression data are given as 22DDCT 6 SEM with the sample size in parentheses. Additionally, the affiliation to LTD, LTP, and the Ca
2+-signaling pathway is given
for each gene. More microarray and qPCR data including non-changed and other significantly changed signaling components are given in Tables S4 and S5 in File S1.
*P#0.05, **P#0.01, ***P#0.001.
doi:10.1371/journal.pone.0092605.t001
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subunit of protein kinase A (PKA) and phosphodiesterase 4b
(PDE4b) were significantly down-regulated in RGS9-deficient
mice (Table 1).
Many genes that are involved in Ca2+ signaling where down-
regulated in striata of RGS9-deficient mice (Table 1) among them
the metabotropic glutamate receptor 5 (mGluR5), the ionotropic
glutamate receptor subunit a2 (GluR2), Ca2+-dependent proteins
like calmodulin (CaM1), Ca2+/CaM-dependent protein kinase II
(CaMK II), phospholipase C (PLCb1) and a catalytic subunit of
protein kinase C (PKC). We also investigated expression levels of
genes encoding endoplasmic membrane proteins that regulate the
cytoplasmic Ca2+ concentration, the ryanodine- (Ryr1) and inositol
1,4,5-trisphosphate receptors (Itpr1) receptor genes and the most
abundant striatal sarco2/endoplasmic reticular Ca2+ ATPase
(SERCA) gene (Atp2a2). While there was no significant alteration
in the IP3R1 expression level, Ryr1 and SERCA2 were
significantly down-regulated (Table S4 in File S1, Table 1). The
intracellular localization and functional interaction of proteins
differentially expressed on the transcript level in striata of RGS9-
deficient mice is illustrated in Figure 1.
Expression and Phosphorylation State of Striatal
Signaling Proteins
To assess the functional relevance of the striatal gene regulation
pattern detected in mRNA expression experiments, we subjected
striatal homogenates of wt and RGS9-deficient mice to Western
blot analyses and quantified selected proteins involved in Ca2+
signaling and synaptic plasticity. The dopamine- and cAMP-
regulated phosphoprotein of 32 kDa (DARPP32) is a key
component in the integration of dopaminergic and glutamatergic
signaling and is highly enriched in striatal tissue [33–35]. To
evaluate differences in RNA expression data from microarray (no
regulation) and qPCR (down-regulation in RGS9-deficient mice)
DARPP32 protein levels were determined in Western blot analysis
revealing no significant difference between both mouse strains
(Fig. 2a). DARPP32 activity is regulated by phosphorylation and
possesses four functional relevant phosphorylation sites: Thr34,
Thr75, Ser102 and Ser137 [36]. Using phosphorylation-specific
antibodies, we quantified relative phosphorylation state levels of
the most important phosphorylated forms of DARPP32,
pDARPP32-Thr34 and pDARPP32-Thr75. Interestingly, phos-
phorylation of DARPP32 was significantly increased at Thr34, but
not at Thr75 (Fig. 2b).
The extracellular signal-regulated kinases 1 and 2 (ERK1 and
ERK2) are downstream effectors of dopamine signaling that
Figure 1. Intracellular localization and functional interaction of selected signaling components expressed in striatum. Transcripts of
signaling components that are significantly downregulated in striata of RGS9-deficient mice are shown in red. The full notations of the transcripts are
given in Table 1 and Table S4 (in File S1).
doi:10.1371/journal.pone.0092605.g001
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regulate excitability and glutamatergic transmission in striatal
sMSN [37]. The ERK activities are tightly regulated by
phosphorylation. Although ERK1 and ERK2 mRNA levels
(Table 1, Table S4 in File S1) and protein concentrations
(Fig. 3a) were lower in RGS9-deficient mice, ERK1/2 phosphor-
ylation was strongly increased (Fig. 3b) indicating sustained
activation.
Control of glutamatergic transmission is also dependent on Ca2+
signaling. Thus, we investigated concentration of Ca2+-dependent
proteins, e.g. CaMK IIb and CaMK IIc (Fig. 4a, b). Furthermore,
protein concentration of GluR2, the most abundant striatal
AMPA receptor subunit that accounts for Ca2+ impermeability
of AMPA receptors [38], was determined (Fig. 4c). In agreement
with gene expression data, protein concentration of CaMK IIc
and GluR2 were significantly decreased in RGS9-deficient mice.
Western blot analysis also revealed a reduced concentration of
CaMK IIb and phospho-CaMK IIb in RGS9-deficient mice but
tendencies were not significant.
Functional Analysis in Acute Striatal Samples
The hyperphosphorylation of DARPP32-Thr34, that was
observed in RGS9-deficient mice (Fig. 2b), implies enhanced
basal PKA activity or an imbalance in the activities of the
opposing D1R and D2R signaling [36] (Fig. 1). To dissect
pathways involved hyperphosphorylation of DARPP32 we
assessed basal and stimulated adenylyl cyclase activity in acute
striatal samples of wt and RGS9-deficient mice by a label-free
AlphaScreen-based cAMP accumulation assay (Fig. 5). Under
basal conditions and forskolin stimulation RGS92/2 samples had
a tendency toward higher adenylyl cyclase activity, however the
tendency was not significant at the individual data point (Fig. 5a).
No significant differences between wt and of RGS92/2 striatal
samples were seen in quinpirole-induced D2R signaling following
forskolin stimulation (Fig. 5b) although the D2R levels appear to
be per se below functional detection limits of the assay.
Figure 2. Striatal DARPP32-Thr34 phosphorylation is enhanced in RGS9-deficient mice. (a) Total DARPP32 from striatal homogenates of
3-month-old wt and RGS9-deficient mice was measured by Western blot quantification and normalized to actin. (b) DARPP32 phosphorylation at
Thr34 and Thr75 is given relative to total DARPP32. Representative Western blots are shown, quantification was performed with n = 6–8 per
genotype.
doi:10.1371/journal.pone.0092605.g002
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Analysis of Spontaneous Synaptic Events
The expression data (Table 1, Table S4 in File S1, Fig. 4)
indicate that GluR2 may be primarily involved in conferring
changes in signal transduction induced by the lack of RGS9. Ca2+
permeability of AMPA receptors is markedly influenced by subunit
composition of these receptors with GluR2 decreasing Ca2+
permeability. In fact, overexpression of Ca2+-permeable receptors
can markedly harm cellular integrity and lead to neurodegener-
ation [39]. In addition, the ratio of GluR1 to GluR2 also correlates
to the amplitude of spontaneous excitatory postsynaptic potentials
(sEPSPs) [40]. The significant reduction of GluR2 expression
detected in striata of RGS9-deficient mice (Table 1, Fig. 4c)
suggests a change in the GluR1:GluR2 ratio and hence a change
in the amplitude of sEPSPs. To test this we analyzed sEPSPs in
sMSN derived from wt and RGS9-deficient mice (Fig. 6). sEPSPs
did not only exhibit larger amplitudes in RGS9-deficient animals
(210.0860.77 vs 27.8560.69 pA) but also occurred at a higher
frequency (6.3160.66 vs 3.2160.44 Hz). All sEPSPs in these cells
were completely blocked by CNQX which confirms that these are
originated by AMPA receptor activation. We cannot completely
exclude that these changes found are exclusively related to
postsynaptic AMPA receptors since AMPA receptors are also
found presynaptically. However, our expression data strongly
suggest that changes in mRNA expression levels mainly derived
from sMSN.
Analysis of Long Term Depression (LTD)
Ionotropic glutamate receptors are involved in synaptic
plasticity and long term changes following tetanic stimuli. Using
Mg2+-containing solutions and current clamp mode, LTD, a
major type of synaptic plasticity, is well recognized in sMSN and
mostly attributed to activation of AMPA receptors. NMDA
receptors should not be involved due to voltage and magnesium
blocks. LTD is dependent on the expression of GluR2 in cerebellar
Purkinje cells [41] and LTD in midbrain dopaminergic neurons
depends on the rapid insertion of GluR2 [42]. As GluR2 transcript
and protein concentration are significantly reduced in RGS92/2
striata, LTD should be dampened in RGS92/2 compared to wt
striata. In fact, when we applied tetanic stimuli and recorded
evoked EPSPs over at least 30 min, we observed LTD of,10% in
RGS9-deficient animals and ,35% in wt animals (Fig. 7).
Discussion
Previous studies have employed the RGS9-deficient mouse
strain as a genetic model system for potentiated D2R-dependent
Figure 3. Striatal ERK1 and ERK2 expression are decreased in RGS9-deficient mice but phosphorylation is increased. (a) Total ERK1
and ERK2 from striatal homogenates of 3-month-old wt and RGS9-deficient mice was measured by Western blot quantification and normalized to
actin. (b) Striatal phospho-ERK1/2 relative to total ERK1/2. Representative Western blots are shown, quantification was performed with n= 7 per
genotype.
doi:10.1371/journal.pone.0092605.g003
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striatal dopaminergic signal transduction [16]. Indeed, our gene
expression data are highly consistent with striatopallidal D2R
hyperactivity in RGS9-deficient mice which is counteracted
through changes in mRNA expression levels of specific down-
stream signaling components. Transcript levels of all G-protein ai
subunits, the downstream signaling components of G-protein bc
heterodimers, PLCb1 and the diacylglycerol- (DAG) and Ca2+-
dependent protein kinase C b1 (PKCb1) were significantly down-
regulated. These findings can be interpreted as compensatory
regulation to counteract persistent overactivity of D2R-dependent
signaling. Unchanged basal cAMP levels in acute striatum biopsies
of wt and ko mice (Fig. 5a) may reflect the effectiveness of these
changes at the functional level and/or the minor importance of
AC inhibition by striatal D2R signal transduction. Indeed, we did
Figure 4. Western blot analyses of key proteins in striata of 3-month-old wt and RGS9-deficient mice. (a) CaMK IIb expression (56 kDa)
and phospho-CaMK IIb expression (60 kDa) were not significantly changed in striata of RGS9-deficient mice. Phospho-CaMK IIb is given relative to
total CaMK IIb. (b, c) CaMK IIc expression and GluR2 expression were significantly decreased in striata of RGS9-deficient mice. Data were normalized
to actin. Representative Western blots are shown, quantification was performed with n = 6 (a, b) and n=7 (c) per genotype.
doi:10.1371/journal.pone.0092605.g004
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not detect adenylyl cyclase inhibition by the D2R-specific agonist
quinpirole in both wt and RGS9-deficient mice (Fig. 5b). The
obvious lack of quinpirole-induced cAMP reduction is in
agreement with a recent study in rat striatal tissue homogenates
[43] suggesting that adenylyl cyclase inhibition is not a significant
downstream effect of striatal D2R activation. Relevant D2R-
signaling mechanisms in striatopallidal sMSN include activation of
PLCb isoforms [44], inhibition of Cav2 channels [45–46] and
opening of potassium channels [47–48] through interaction with
G-protein bc heterodimers. While the former leads to intracellular
Ca2+ mobilization, the last two mechanisms result in a dopamine-
dependent reduction in neuronal excitability.
There is evidence from our transcriptome data that components
of the intracellular D1R/Gs protein/AC signaling cascade (AC 3
Figure 5. D2R activation does not inhibit forskolin-stimulated cAMP formation in acute striatal samples. (a) Forskolin increases cAMP
accumulation in acute striatum biopsies from both wt and RGS9-deficient mice with an EC50 of 2.6 mM (n=4). (b) Acute striatum samples
prestimulated with 10 mM forskolin were incubated with the selective D2R agonist quinpirole at concentrations from 10 nM to 100 mM. No reduction
in cAMP accumulation was detected at sub-micromolar concentrations. Similar results were obtained when 60 mM forskolin were used for
prestimulation (data not shown).
doi:10.1371/journal.pone.0092605.g005
Figure 6. sEPSP in sMSN from wt and RGS9-deficient mice. sEPSP in sMSN from wt and RGS9-deficient mice. (a) sMSN with multiple dendrites
and a large number of spines, i.e. a typical morphology in wt. (b) Characteristic whole-cell currents showing enhanced sEPSP in RGS92/2 cells. (c)
Example of voltage clamp traces of RGS92/2 sMSN. (d–f) Quantification of amplitudes (d), inter-event interval (e) and frequency (f) of sEPSPs
indicating larger and more frequent sEPSPs in RGS9-deficient animals (*P#0.05, n = 21 (wt) and 18 (ko), respectively).
doi:10.1371/journal.pone.0092605.g006
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and 7, b subunit of PKA) are significantly down-regulated in
RGS9-deficient mice. Together with the similar cAMP responses
to forskolin (Fig. 5) this may point towards a compensation of
increased stimulation via D1R. Secondly, key substrates of PKA
that regulate striatal control of motor function include AMPA
receptors and Thr34 of DARPP32. In agreement with PKA
overactivity, significantly enhanced phosphorylation of DARPP32-
Thr34 but not of Thr75 was detected in Western blot experiments
(Fig. 2). In DARPP32, Thr34- and Thr75 phosphorylations have
mutually antagonistic effects with the phospho-Thr34 form acting
as an endogenous inhibitor of protein phosphatase 1. Overactivity
of these intracellular effectors and the most abundant striatal
AMPA receptor subunit GluR2 is also reflected by down-
regulation of the respective transcripts and proteins (Table 1,
Fig. 4c).
PLCb activation is one of the intracellular key events after
activation of D2R in striatopallidal sMSN [44]. Inositol trispho-
sphate release by PLCb triggers the liberation of Ca2+ from the
endoplasmic reticulum (Fig. 1). The time course of the intracellular
Ca2+ signal is further shaped by Ca2+-induced Ca2+ release from
the endoplasmic reticulum, a process that involves ryanodine
receptors. Both transcripts Plcb1 and Ryr1, as well as protein
kinase C (PKC), a target of the other second messenger released by
PLC, diacylglycerol (DAG), were significantly down-regulated in
RGS9-deficient mice. In fact, down-regulation of the Ryr1
transcript by a factor of 0.19 was the strongest gene regulation
effect observed in RGS9-deficient mice. This is likely to represent
an adaptive response to substantially potentiated Ca2+ signaling in
striatopallidal sMSN. A somewhat puzzling finding is that the
ATP2a2 transcript that codes for the most prevalent neuronal
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) isoenzyme is
also significantly down-regulated. SERCA enzymes participate in
the control of [Ca2+]i by sequestering Ca
2+ into the endoplasmic
reticulum (Fig. 1). However, in a recent study, profound loss of
striatal SERCA activity was also found in an animal model of
excitotoxicity that is associated with excessive Ca2+ influx [49].
Further stimulation of PLCb isoenzymes comes from Gq/11
protein-coupled receptors, particularly class I metabotropic
glutamate receptors. Both mGluR5 and the G-protein aq subunit
were also significantly down-regulated in RGS92/2 striata
(Table 1). Taken together, the described effects may result in
exaggerated Ca2+ release in striatopallidal sMSN. This finding
would also be consistent with the above mentioned circuitry-based
increased glutamatergic stimulation of RGS92/2 striata.
The intracellular Ca2+ concentration ([Ca2+]i) controls a
plethora of cellular effects, an action that is in many cases
mediated by the intracellular Ca2+ sensor calmodulin (CaM). In
sMSN, this includes regulation of gene transcription, cellular
excitability and long-term modulation of ionotropic glutamatergic
transmission. Many processes that control synaptic transmission
including AMPA receptor function [50] and synaptic delivery [51]
are subject to regulation by the Ca2+/CaM-dependent kinase II
(CaMK II). Both, the CaM and CaMK II (isoforms b and c)
transcripts were significantly down-regulated (Table 1) indicating
sustained activity of this pathway. Enhanced synaptic AMPA
receptor activity is also functionally reflected in the significantly
increased amplitude and frequency of sEPSP in voltage-clamp
experiments (Fig. 6).
AMPA receptors are heterotetrameric complexes in which the
presence of the GluR2 subunit defines the endogenous imperme-
ability to Ca2+ [38]. There is, however, increasing evidence that
Ca2+-permeable forms of AMPA receptors may participate in
striatal plasticity [52]. Both qPCR and Western blot experiments
demonstrated significantly reduced striatal expression of GluR2 in
RGS9-deficient mice (Table1; Fig. 4c). This favors the formation
of Ca2+-permeable AMPA receptors that may contribute to
excessive Ca2+ signaling and altered long-term synaptic plasticity
in sMSN.
LTD is the most prominent form of synaptic plasticity in the
dorsal striatum. Studies in transgenic mice in which direct and
indirect pathway sMSN were labeled by selective GFP expression
revealed that high-frequency stimulation-induced LTD is a
specific feature of D2R-expressing indirect pathway sMSN [53].
There is evidence that the underlying mechanism depends on the
postsynaptic release of endocannabinoids in a process that involves
D2R stimulation, L-type Ca2+ channels and group I metabotropic
glutamate receptors (mGluR1, mGluR5) in a coordinated way
[54–57]. The striking reduction in synaptic LTD in RGS92/2
sMSN (Fig. 7) may be the result of mGluR5 down-regulation or
attenuation of the intracellular D2R signaling cascade. The
marked disturbances in working memory that have been
previously described in RGS9-deficient animals [19] may be a
behavioral correlate to this finding.
Figure 7. Reduced synaptic plasticity in RGS9-deficient mice. (a) EPSPs in sMSN before and 30 min after tetanic stimulation of glutamatergic
afferents. (b) Normalized amplitudes of evoked EPSPs during the last 5 minutes of baseline stimulation and during the first 30 minutes following
tetanic stimulation. Note the expected reduction of amplitudes in wt animals which was not seen in RGS9-deficient animals (*P#0.05, n = 10 (ko) and
9 (wt), respectively).
doi:10.1371/journal.pone.0092605.g007
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We also found an increased ERK1/2 phosphorylation (Fig. 3).
However, this does not result from enhanced Ca2+ signaling and
CaMK II overactivity because Western blot analysis revealing no
significant difference in phosphorylation state of CaMK IIb in
RGS9-deficient mice (Fig. 4a). A number of studies indicate that
ERK1/2 phosphorylation underlies striatal regulation of gene
expression and long-term synaptic plasticity [58]. In a mouse
model of drug-induced dyskinesia, sensitized cAMP/PKA signal-
ing activated ERK1/2 [59], a pathway that is confined to D1R-
expressing sMSN [60–61].
It remains unclear, how constitutively potentiated D2R activity
in RGS9-deficient mice modulates D1R-dependent transmission
and whether this crosstalk occurs in the same sMSN. However, a
significant subset of MSN (20–50% depending on the striatal area)
but not all coexpress both D1R and D2R [62–64]. In a previous
study that analyzed striatal dopaminergic signal transduction in
mice deficient for the G-protein ao splice variant, attenuation of
D2R signaling resulted in concomitant down-regulation of D1R-
signaling components and diminished behavioral sensitization in
response to cocaine [65]. Enhancement of D1R transmission in
RGS9-deficient mice may thus be an analogous compensatory
response on a functional level to D2R overactivity. We cannot
answer whether these compensatory responses involve alterations
of the activity of the basal ganglia loop based on the data
presented. However, the basic model relating to direct and indirect
signaling pathways in the basal ganglia would predict, that
increased D2R signaling of sMSN lead to decreased activity of
subthalamic nucleus and medial pallidal (GPi) output neurons and
subsequent overactivity of cortical motor neurons [66], which in
turn would overstimulate sMSN. Our present data provide at least
some evidence that such glutamatergic overstimulation may share
alterations of downstream signaling molecules such as DARPP32
and ERK.
In summary, RGS9-deficient mice show significant changes in
striatal function including enhanced DARPP32 and ERK
phosphorylation that are characteristically found in L-DOPA-
induced dyskinesia [59,67]. In this study, we have shown that
striata of RGS9-deficient mice present changes in transcript levels
of Ca2+ signaling components that may counteract D2R overac-
tivity. Thus, prolonged dopamine depletion that releases the
pressure on gene regulation unmasks dyskinesia in these animals.
By analyzing specific gene expression in RGS9-deficient mice, we
have identified a number of critical signaling components that may
represent novel targets in antidyskinetic therapy.
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